Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESTABLISH-2: Tedizolid vs Linezolid in ABSSSI
NCT01421511Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2011
- Primary completion
- Jan 2013
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial of tedizolid in acute bacterial skin and skin structure infections (ABSSSI), sponsored by Merck & Co. Primary endpoint: Early Clinical Response Rate. Started Sep 2011; status: completed.
02
Drugs
tedizolid
03
Conditions
acute bacterial skin and skin structure infections (ABSSSI)
Beyond the preview
Go deeper on NCT01421511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01421511.